Investing.com -- Ernexa Therapeutics Inc (NASDAQ:ERNA) stock fell 3.4% Monday despite the company’s presentation of promising preclinical data for its lead cell therapy candidate at the American Society of Hematology Annual Meeting.
The Cambridge, Massachusetts-based company shared results showing that ERNA-101, its proprietary cell therapy platform, can reprogram immunosuppressive tumor microenvironments into immune-active states to fight cancer. The data demonstrated that engineered induced pluripotent stem cells transformed into mesenchymal stem cells showed potential in overcoming resistance in both solid tumors and blood cancers.
In an immunocompetent ovarian cancer model, administration of the company’s IL-7/IL-15-secreting iMSCs resulted in significant immune cell infiltration into tumors and prolonged survival. The engineered cells achieved cytokine production levels approximately 20-fold higher than previously reported in engineered T-cell approaches.
"These data represent an important validation of our platform and reinforce our belief that iPSC-derived MSCs can be engineered into powerful immune-modulating agents," said Sanjeev Luther, President & CEO of Ernexa Therapeutics.
The study, conducted with MD Anderson Cancer Center, showed tumors transitioning from an immune-excluded "cold" state to a highly inflamed "hot" microenvironment, which is considered necessary for responsiveness to modern immunotherapies.
Ernexa is advancing ERNA-101 through additional preclinical testing, with first-in-human trials planned for next year. The company positions its approach as potentially advantageous by providing a scalable, off-the-shelf treatment without requiring patient-specific cell harvesting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








